IL290251B2 - Combination for the effective treatment of metastatic cancer in patients - Google Patents
Combination for the effective treatment of metastatic cancer in patientsInfo
- Publication number
- IL290251B2 IL290251B2 IL290251A IL29025122A IL290251B2 IL 290251 B2 IL290251 B2 IL 290251B2 IL 290251 A IL290251 A IL 290251A IL 29025122 A IL29025122 A IL 29025122A IL 290251 B2 IL290251 B2 IL 290251B2
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- dose
- ascorbic acid
- hydroxocobalamin
- melphalan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263880P | 2015-12-07 | 2015-12-07 | |
| PCT/US2016/065079 WO2017100162A1 (en) | 2015-12-07 | 2016-12-06 | Combination for the effective treatment of metastatic cancer in patients |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL290251A IL290251A (en) | 2022-04-01 |
| IL290251B1 IL290251B1 (en) | 2024-03-01 |
| IL290251B2 true IL290251B2 (en) | 2024-07-01 |
Family
ID=57708742
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL290251A IL290251B2 (en) | 2015-12-07 | 2016-12-06 | Combination for the effective treatment of metastatic cancer in patients |
| IL259512A IL259512B2 (en) | 2015-12-07 | 2016-12-06 | Combination for the effective treatment of metastatic cancer in patients |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL259512A IL259512B2 (en) | 2015-12-07 | 2016-12-06 | Combination for the effective treatment of metastatic cancer in patients |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11154520B2 (https=) |
| EP (1) | EP3386546B1 (https=) |
| JP (3) | JP6831853B2 (https=) |
| KR (1) | KR20180086257A (https=) |
| AU (2) | AU2016367112B2 (https=) |
| CA (1) | CA3044959C (https=) |
| DK (1) | DK3386546T3 (https=) |
| ES (1) | ES2994931T3 (https=) |
| FI (1) | FI3386546T3 (https=) |
| HU (1) | HUE069668T2 (https=) |
| IL (2) | IL290251B2 (https=) |
| PL (1) | PL3386546T3 (https=) |
| PT (1) | PT3386546T (https=) |
| WO (1) | WO2017100162A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3388060A1 (en) | 2012-10-22 | 2018-10-17 | Arnold Glazier | Methods for the effective treatment of metastatic cancer |
| WO2017214140A1 (en) * | 2016-06-06 | 2017-12-14 | University Of Iowa Research Foundation | Compositions and methods for cancer therapy |
| EA202190580A1 (ru) | 2018-08-21 | 2021-06-25 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Системз | Композиции и способы для лечения злокачественных клеток посредством индукции цитотоксического оксидативного стресса |
| CN114904011B (zh) * | 2021-07-06 | 2023-10-13 | 中国科学院上海硅酸盐研究所 | 非铁基谷胱甘肽消耗协同活性氧物种增强复合材料及其制备方法和应用 |
| EP4376822A4 (en) * | 2021-07-29 | 2025-09-17 | Lantern Pharma Inc | TREATMENT OF CANCER WITH COMBINATIONS OF PARP INHIBITORS AND ACYLFULVENS |
| CN116407557A (zh) * | 2023-05-29 | 2023-07-11 | 四川大学华西医院 | 一种防治出血性脑卒中的药物组合物及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150265641A1 (en) * | 2012-10-22 | 2015-09-24 | Arnold Glazier | Methods for the Effective Treatment of Metastatic Cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1305873C (en) * | 1987-05-26 | 1992-08-04 | Howel Gwynne Giles | Method and means for detecting alcohol levels in humans |
| US5639787A (en) | 1995-02-28 | 1997-06-17 | The Center For The Improvement Of Human Functioning Int'l, Inc. | Therapeutic method for the treatment of cancer |
| WO2000076556A2 (en) | 1999-06-11 | 2000-12-21 | Neorx Corporation | High dose radionuclide complexes for bone marrow suppression |
| EP1313508B1 (en) * | 2000-06-30 | 2007-04-18 | Eli Lilly And Company | Combination containing an antifolate and methylmalonic acid lowering agent |
| EP1485720B1 (en) * | 2002-03-22 | 2008-03-12 | Ludwig Maximilians Universität | Cytocapacity test |
| ES2421516T3 (es) | 2002-11-06 | 2013-09-03 | Dana Farber Cancer Inst Inc | Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341 |
| US20090123447A1 (en) * | 2007-11-14 | 2009-05-14 | The Regents Of The University Of California | Compositions and methods to inhibit rna viral reproduction |
| US9050265B2 (en) * | 2009-07-20 | 2015-06-09 | Summa Health System | Vitamin C and vitamin K, and compositions thereof for treatment of osteolysis or prolongation of prosthetic implant |
-
2016
- 2016-12-06 EP EP16820404.8A patent/EP3386546B1/en active Active
- 2016-12-06 PT PT168204048T patent/PT3386546T/pt unknown
- 2016-12-06 FI FIEP16820404.8T patent/FI3386546T3/fi active
- 2016-12-06 HU HUE16820404A patent/HUE069668T2/hu unknown
- 2016-12-06 US US15/778,796 patent/US11154520B2/en active Active
- 2016-12-06 WO PCT/US2016/065079 patent/WO2017100162A1/en not_active Ceased
- 2016-12-06 CA CA3044959A patent/CA3044959C/en active Active
- 2016-12-06 ES ES16820404T patent/ES2994931T3/es active Active
- 2016-12-06 KR KR1020187019041A patent/KR20180086257A/ko not_active Ceased
- 2016-12-06 AU AU2016367112A patent/AU2016367112B2/en active Active
- 2016-12-06 IL IL290251A patent/IL290251B2/en unknown
- 2016-12-06 JP JP2018549135A patent/JP6831853B2/ja active Active
- 2016-12-06 IL IL259512A patent/IL259512B2/en unknown
- 2016-12-06 DK DK16820404.8T patent/DK3386546T3/da active
- 2016-12-06 PL PL16820404.8T patent/PL3386546T3/pl unknown
-
2021
- 2021-01-29 JP JP2021013001A patent/JP7144554B2/ja active Active
- 2021-10-13 US US17/500,169 patent/US20220096405A1/en not_active Abandoned
-
2022
- 2022-01-11 AU AU2022200131A patent/AU2022200131A1/en not_active Abandoned
- 2022-09-15 JP JP2022147352A patent/JP2022171816A/ja active Pending
-
2024
- 2024-01-09 US US18/408,066 patent/US20240216308A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150265641A1 (en) * | 2012-10-22 | 2015-09-24 | Arnold Glazier | Methods for the Effective Treatment of Metastatic Cancer |
Non-Patent Citations (1)
| Title |
|---|
| AKATOV, V.S. ET AL.,, OXIDATIVE STRESS IN HEP-2 HUMAN LARYNGEAL CARCINOMA CELLS INDUCED BYCOMBINATION OF VITAMINS B12B AND C,, 31 December 2003 (2003-12-31) * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021073262A (ja) | 2021-05-13 |
| HUE069668T2 (hu) | 2025-04-28 |
| JP6831853B2 (ja) | 2021-02-17 |
| IL290251B1 (en) | 2024-03-01 |
| IL259512B1 (en) | 2023-11-01 |
| EP3386546B1 (en) | 2024-09-04 |
| PL3386546T3 (pl) | 2025-01-27 |
| US11154520B2 (en) | 2021-10-26 |
| KR20180086257A (ko) | 2018-07-30 |
| PT3386546T (pt) | 2024-12-09 |
| WO2017100162A1 (en) | 2017-06-15 |
| IL259512B2 (en) | 2024-03-01 |
| EP3386546A1 (en) | 2018-10-17 |
| US20220096405A1 (en) | 2022-03-31 |
| FI3386546T3 (fi) | 2024-12-05 |
| ES2994931T3 (en) | 2025-02-04 |
| IL290251A (en) | 2022-04-01 |
| AU2016367112A1 (en) | 2018-07-12 |
| AU2016367112B2 (en) | 2022-01-13 |
| CA3044959C (en) | 2024-01-09 |
| DK3386546T3 (en) | 2024-11-25 |
| US20240216308A1 (en) | 2024-07-04 |
| JP2022171816A (ja) | 2022-11-11 |
| JP7144554B2 (ja) | 2022-09-29 |
| CA3044959A1 (en) | 2017-06-15 |
| AU2022200131A1 (en) | 2022-02-10 |
| IL259512A (en) | 2018-07-31 |
| US20180338935A1 (en) | 2018-11-29 |
| JP2019501962A (ja) | 2019-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7144554B2 (ja) | 患者における転移性癌の有効な治療のための組合せ | |
| Tao et al. | Targeting hypoxic tumor microenvironment in pancreatic cancer | |
| Mocellin et al. | Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities | |
| Coleman et al. | 2-deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer | |
| Heffner et al. | Pulmonary strategies of antioxidant defense 1 | |
| US20240024344A1 (en) | Methods For The Effective Treatment Of Metastatic Cancer | |
| Zarei et al. | IDH1 inhibition potentiates chemotherapy efficacy in pancreatic cancer | |
| CA3152258A1 (en) | Compositions and methods for treating metastatic gastrointestinal cancer | |
| Li | Vitamin C, a multi-tasking molecule, finds a molecular target in killing cancer cells | |
| Shi et al. | Anti‐Tumor Strategies Targeting Nutritional Deprivation: Challenges and Opportunities | |
| Liu et al. | Application of hypoxia-activated prodrugs in tumor therapy: Design strategies and perspectives | |
| HK1261631A1 (en) | Combination for the effective treatment of metastatic cancer in patients | |
| HK40039081A (en) | Methods for the effective treatment of metastatic cancer | |
| Ogochukwu | Ascorbic acid in cancer management–time for a second look | |
| Zaidieh | ROS and mitochondrial genetic abnormalities as novel indicators to predict anticancer drug efficacy | |
| Kloepping | Mitochondria-targeted therapy for metastatic melanoma | |
| Bruchelt et al. | Glucose Metabolism and the Antioxidative Defense System in Cancer Cells: Options for the Application of ROS-based Anticancer Drugs | |
| Huxham | The tumour microenvironment: mapping the microregional effects of drugs | |
| TARGET et al. | RA TIONAL ENZY.-DIRECTE~ A PRODRUG DEVE OPMENT | |
| Ballerini et al. | Gasotransmitters bridging tumor biology and immunity: from pathophysiological insights to therapeutic potential | |
| Rawal | Manganoporphyrins as adjuvants to enhance pharmacological ascorbate in pancreatic cancer therapy | |
| Millard | Discovery of novel small molecules targeting cancer cell metabolism |